Rationale for and Design of the CREATIVE-AF TrialRandomized, Double-Blind, Placebo-Controlled, Crossover Study of the Effect of Irbesartan on Oxidative Stress and Adhesion Molecules in Patients with Persistent Atrial Fibrillation

被引：0

作者：

Andreas Goette

Alessandra D’Alessandro

Alicja Bukowska

Siegfried Kropf

Christian Mewis

Christoph Stellbrink

Jürgen Tebbenjohanns

Christian Weiss

Uwe Lendeckel

机构：

[1] Otto-von-Guericke-University Hospital,Department of Cardiology

[2] Otto-von-Guericke-University Hospital,Institute for Experimental Internal Medicine

[3] Otto-von-Guericke-University Hospital,Institute for Biometry and Medical Informatics

[4] University of Saarland,Hospital for Internal Medicine III

[5] Städtische Kliniken Bielefeld,II. Medical Hospital and Ambulance

[6] STK Hildesheim,undefined

[7] Johannes Gutenberg-University Mainz,undefined

来源：

Clinical Drug Investigation | 2008年 / 28卷

关键词：

Atrial Fibrillation; Irbesartan; Oxidative Stress Marker; Persistent Atrial Fibrillation; Oxidative Stress Parameter;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 receptors by irbesartan reduces levels of circulating adhesion molecules and oxidative stress parameters in patients with persistent AF by 25% compared with placebo.

引用

页码：565 / 572

页数：7